Logo image of IZTC

INVIZYNE TECHNOLOGIES INC (IZTC) Stock Fundamental Analysis

NASDAQ:IZTC - Nasdaq - US4618741098 - Common Stock - Currency: USD

16.5  +1 (+6.45%)

Fundamental Rating

1

Overall IZTC gets a fundamental rating of 1 out of 10. We evaluated IZTC against 557 industry peers in the Biotechnology industry. IZTC has a bad profitability rating. Also its financial health evaluation is rather negative. IZTC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IZTC had negative earnings in the past year.
IZTC Yearly Net Income VS EBIT VS OCF VS FCFIZTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -500K -1M -1.5M -2M

1.2 Ratios

IZTC has a Return On Assets of -57.25%. This is comparable to the rest of the industry: IZTC outperforms 43.34% of its industry peers.
Industry RankSector Rank
ROA -57.25%
ROE N/A
ROIC N/A
ROA(3y)-53.6%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IZTC Yearly ROA, ROE, ROICIZTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 200 400

1.3 Margins

IZTC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IZTC Yearly Profit, Operating, Gross MarginsIZTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, IZTC has about the same amount of shares outstanding.
There is no outstanding debt for IZTC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IZTC Yearly Shares OutstandingIZTC Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2M 4M 6M 8M
IZTC Yearly Total Debt VS Total AssetsIZTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 1M 2M 3M

2.2 Solvency

An Altman-Z score of 4.12 indicates that IZTC is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.12, IZTC is in the better half of the industry, outperforming 78.51% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 4.12
ROIC/WACCN/A
WACCN/A
IZTC Yearly LT Debt VS Equity VS FCFIZTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 1M -1M -2M

2.3 Liquidity

IZTC has a Current Ratio of 0.25. This is a bad value and indicates that IZTC is not financially healthy enough and could expect problems in meeting its short term obligations.
IZTC has a Current ratio of 0.25. This is amonst the worse of the industry: IZTC underperforms 96.45% of its industry peers.
A Quick Ratio of 0.25 indicates that IZTC may have some problems paying its short term obligations.
IZTC's Quick ratio of 0.25 is on the low side compared to the rest of the industry. IZTC is outperformed by 96.27% of its industry peers.
Industry RankSector Rank
Current Ratio 0.25
Quick Ratio 0.25
IZTC Yearly Current Assets VS Current LiabilitesIZTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 500K 1M 1.5M 2M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for IZTC have decreased strongly by -46.01% in the last year.
EPS 1Y (TTM)-46.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IZTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IZTC Price Earnings VS Forward Price EarningsIZTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IZTC Per share dataIZTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IZTC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INVIZYNE TECHNOLOGIES INC

NASDAQ:IZTC (2/11/2025, 8:00:02 PM)

16.5

+1 (+6.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners1.21%
Inst Owner Change-21.75%
Ins Owners27.99%
Ins Owner Change0.03%
Market Cap134.15M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.25
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS-0.44
TBVpS-0.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -57.25%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.6%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.25
Quick Ratio 0.25
Altman-Z 4.12
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)327.93%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-46.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-34.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.06%
OCF growth 3YN/A
OCF growth 5YN/A